Open access
Open access
Powered by Google Translator Translator

Infectious Diseases (all articles)

Review: Changing paradigms in the management of acute uncomplicated diverticulitis.

30 Jul, 2021 | 11:37h | UTC

Changing Paradigms in the Management of Acute Uncomplicated Diverticulitis – Scandinavian Journal of Surgery

Related:

RCT: Another study shows that non-antibiotic outpatient treatment in mild acute diverticulitis is safe.

Review: Elective surgical management of diverticulitis

State of the Art Review | Management of colonic diverticulitis

Drains, germs, or steel: Multidisciplinary management of acute colonic diverticulitis

Diverticulitis: Observational study in outpatients suggests amoxicillin-clavulanate is a safe and effective option compared with metronidazole-fluoroquinolone

Randomized trial: Laparoscopic lavage vs. primary resection for perforated purulent diverticulitis; similar long-term results, but recurrence was more common after laparoscopic lavage

Randomized trial: In patients with recurrent, complicated, or persistent painful diverticulitis, sigmoid resection improved quality of life but was associated with a small but significant risk of major complications

Systematic review: Management of colonic diverticulitis

WSES Guidelines for the Management of Acute Colonic Diverticulitis

ASCRS Guidelines for the Treatment of Left-Sided Colonic Diverticulitis

 

Commentary on Twitter

https://twitter.com/ScandJSurg/status/1420655333815427084

 

Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.

29 Jul, 2021 | 11:38h | UTC

Ivermectin for preventing and treating COVID‐19 – Cochrane Library

Summary: Ivermectin for preventing and treating COVID-19 – Cochrane Library

Commentary: Ivermectin treatment in humans for COVID-19 – Liverpool School of Tropical Medicine

Related:

Why was a major study on ivermectin for covid-19 just retracted?

RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials

RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19

 

Updated WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of limited supply.

29 Jul, 2021 | 11:34h | UTC

WHO SAGE Roadmap For Prioritizing Uses Of COVID-19 Vaccines In The Context Of Limited Supply – World Health Organization

 

PRINCIPLE RCT: Doxycycline does not improve outcomes in outpatients with suspected COVID-19 at high risk for adverse outcomes.

29 Jul, 2021 | 11:36h | UTC

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet Respiratory Medicine

Commentary: PRINCIPLE: a community-based COVID-19 platform trial – The Lancet Respiratory Medicine

 

Commentary on Twitter

https://twitter.com/LancetRespirMed/status/1420302490864603142

 

Covid-19 breakthrough infections in vaccinated health care workers.

29 Jul, 2021 | 11:30h | UTC

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers – New England Journal of Medicine

 

Commentary on Twitter (thread – click for more)

 

COVID-19 false dichotomies and a comprehensive review of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask wearing, and reinfection.

29 Jul, 2021 | 11:32h | UTC

COVID-19 false dichotomies and a comprehensive review of the evidence regarding public health, COVID-19 symptomatology, SARS-CoV-2 transmission, mask wearing, and reinfection – BMC Infectious Diseases

 

Commentary on Twitter

 

COVID vaccines slash viral spread, but Delta is an unknown – “Studies show that vaccines reduce the spread of SARS-CoV-2 by more than 80%, but the Delta variant is creating fresh uncertainty”.

29 Jul, 2021 | 11:21h | UTC

COVID vaccines slash viral spread – but Delta is an unknown – Nature

 

What is a breakthrough infection? 6 questions answered about catching COVID-19 after vaccination.

29 Jul, 2021 | 11:28h | UTC

What is a breakthrough infection? 6 questions answered about catching COVID-19 after vaccination – The Conversation

 

Efficacy of Pfizer/BioNTech Covid vaccine slips to 84% after six months, data show.

29 Jul, 2021 | 11:19h | UTC

Efficacy of Pfizer/BioNTech Covid vaccine slips to 84% after six months, data show – STAT

Original study (preprint): Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine – medRxiv

 

Commentary on Twitter (thread – click for more)

https://twitter.com/hildabast/status/1420481872212070404

 

Evidence Analysis: Is piperacillin-tazobactam safe in patients with penicillin allergy?

29 Jul, 2021 | 11:05h | UTC

Is piperacillin-tazobactam safe in patients with penicillin allergy? – PulmCrit

 

CDC changes mask guidance in response to threat of Delta variant of Covid-19.

28 Jul, 2021 | 10:23h | UTC

Commentary: CDC changes mask guidance in response to threat of Delta variant of Covid-19 – CNN

See guidance: Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage – Centers for Disease Control and Prevention

 

Commentaries on Twitter

 

Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees.

28 Jul, 2021 | 10:19h | UTC

Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis – The Lancet

Related:

WHO Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19).

AHA/ASA Guidance: Diagnosis and Management of Cerebral Venous Sinus Thrombosis with Vaccine-Induced Thrombotic Thrombocytopenia – “No heparin products in any dose should be given.”

ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine Induced Immune Thrombotic Thrombocytopenia

Case series: therapeutic plasma exchange in 3 patients with vaccine-induced immune thrombotic thrombocytopenia.

Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations.

Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.

Laboratory testing for suspected COVID-19 vaccine–induced (immune) thrombotic thrombocytopenia.

Concerned about the latest AstraZeneca news? These 3 graphics help you make sense of the risk – “Two people in Australia have died from thrombosis with thrombocytopenia after 3.8 million doses of the AstraZeneca vaccine delivered”.

Case series: Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia.

Case report: Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).

[Preprint] Meta-analysis of risk of vaccine-induced immune thrombotic thrombocytopenia following ChAdOx1-S recombinant vaccine – Overall risk is 1 in 139,000; for age 65 and over, about 1 in 1,000,000; for age under 55, between 1 in 20,000 to 60,000.

Cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S. 11 excess venous thromboembolic events per 100 000 vaccinations; 2.5 excess cerebral venous thrombosis per 100 000 vaccinations.

Case series of 12 patients with cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination – all women younger than 60 years, with symptoms from 6 to 15 days after vaccination

Vaccine-induced Immune Thrombotic Thrombocytopenia: Frequently Asked Questions

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Editorial: SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia – “The very low prevalence of this complication of vaccination, however severe, relative to the benefits of preventing Covid-19 must be emphasized”

Case Report: Thrombotic Thrombocytopenia after Johnson & Johnson Vaccine

Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine

Guidance on syndrome of Thrombosis and Thrombocytopenia occurring after coronavirus Vaccination

 

Commentary on Twitter

 

Editorial: Nine lessons learned from the Covid-19 pandemic for improving hospital care and health care delivery.

28 Jul, 2021 | 10:17h | UTC

Nine Lessons Learned From the COVID-19 Pandemic for Improving Hospital Care and Health Care Delivery – JAMA Internal Medicine

 

Report: Improved ventilation essential to safe use of buildings and public spaces, say leading engineers.

28 Jul, 2021 | 10:16h | UTC

News release: Improved ventilation essential to safe use of buildings and public spaces, say leading engineers – Royal Academy of Engineering

Report: Infection Resilient Environments: Buildings that keep us healthy and safe – National Engineering Policy Centre

Related:

WHO: Roadmap to improve and ensure good indoor ventilation in the context of COVID-19

CDC releases new ventilation guidelines for indoor environments to reduce Covid-19 risk

Guidance: Using Ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes

 

Commentary on Twitter

https://twitter.com/trishgreenhalgh/status/1419607205565894657

 

Household transmission of SARS-CoV-2 from children and adolescents.

28 Jul, 2021 | 10:08h | UTC

Household Transmission of SARS-CoV-2 from Children and Adolescents – New England Journal of Medicine

Related:

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England – “the likelihood of household transmission was approximately 40 to 50% lower in households of index patients who had been vaccinated 21 days or more before testing positive than in households of unvaccinated index patients”.

Covid-19 vaccination prevents transmission from vaccinated to unvaccinated household members.

Study in England showed one dose of COVID-19 vaccine can cut household transmission by up to half – This protection is on top of the reduced risk of a vaccinated person developing symptomatic infection, which is around 60 to 65% after the first dose

Study: Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity

A meta-analysis on the role of children in SARS-CoV-2 in household transmission clusters

Report: SARS-CoV-2 setting-specific transmission rates. Households showed the highest transmission rates (21.1%). Asymptomatic infections do occur but much less efficiently than symptomatic infection.

CDC Report: Transmission of SARS-COV-2 infections in households

The household secondary attack rate of SARS-CoV-2: A rapid review

 

Commentary on Twitter

 

COVID-19 and mucormycosis superinfection: the perfect storm.

28 Jul, 2021 | 10:09h | UTC

COVID-19 and mucormycosis superinfection: the perfect storm – Infection

Related:

ECMM/ISHAM recommendations for clinical management of COVID -19 associated mucormycosis in low- and middle-income countries.

The “Black Fungus” in India: The Emerging Syndemic of COVID-19–Associated Mucormycosis – careful use of antibiotics and corticosteroids and closely monitoring blood glucose levels are some of the strategies suggested by the authors.

Multicenter Epidemiologic Study of Coronavirus Disease–Associated Mucormycosis, India – Uncontrolled diabetes mellitus was the most common underlying disease; improper glucocorticoid use was independently associated with the disease.

Opinion | “Doctors have been blamed for the rise in black fungus in India, but the COVID treatment guidelines could be contributing” – improper use of antibiotics and higher than usual doses of corticosteroids may be contributing to the emergence of mucormycosis and other fungal co-infections.

What is mucormycosis, the fungal infection affecting COVID patients in India?

[Preprint] The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries.

Mucormycosis: The ‘black fungus’ maiming Covid patients in India

Global Guideline for the Diagnosis and Management of Mucormycosis

 

SARS-COV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis.

28 Jul, 2021 | 10:13h | UTC

SARS-COV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis – American Journal of Obstetrics and Gynecology

 

Moral uncertainty: A case study of Covid-19.

28 Jul, 2021 | 10:05h | UTC

Moral uncertainty: A case study of Covid-19 – Patient Education and Counseling

 

Commentary on Twitter

https://twitter.com/trishgreenhalgh/status/1419648261661528072

 

RCT: 7 days of antibiotic therapy as good as 14 days for afebrile men with urinary tract infection.

28 Jul, 2021 | 10:03h | UTC

Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Shorter Courses of Antibiotics for Urinary Tract Infection in Men (free for a limited period)

Commentary: Study Supports Shorter Antibiotic Course for Afebrile Men With UTI – MPR

 

Commentary on Twitter

 

CDC Report: Transmission of pan-resistant Candida auris in health care facilities.

28 Jul, 2021 | 09:59h | UTC

Notes from the Field: Transmission of Pan-Resistant and Echinocandin-Resistant Candida auris in Health Care Facilities ― Texas and the District of Columbia, January–April 2021 – CDC Morbidity and Mortality Weekly Report

Commentaries:

CDC reports two outbreaks of pan-resistant Candida auris – CIDRAP

U.S. sees first cases of dangerous fungus resistant to all drugs in untreated people – STAT

Related:

Case reports: Multidrug-resistant Candida auris infections in critically ill Covid-19 patients

Candida auris: A Review of Recommendations for Detection and Control in Healthcare Settings

Global Epidemiology of Emerging Candida Auris (reviews and commentaries on the subject)

The superbug Candida auris is giving rise to warnings — and big questions – STAT

Candida Auris – “A Mysterious Infection, Spanning the Globe in a Climate of Secrecy” (reviews and commentaries on the subject)

 

Commentaries on Twitter

 

Review: Long covid—mechanisms, risk factors, and management.

27 Jul, 2021 | 03:52h | UTC

Long covid—mechanisms, risk factors, and management – The BMJ

 

Commentary on Twitter

 

Major medical groups call for employers to mandate Covid-19 vaccines for health care workers.

27 Jul, 2021 | 03:44h | UTC

Major medical groups call for employers to mandate Covid-19 vaccines for health care workers – CNN

Original Document: Joint Statement in Support of COVID-19 Vaccine Mandates for All Workers in Health and Long-Term Care

 

Commentaries on Twitter

 

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

27 Jul, 2021 | 03:48h | UTC

Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination – Nature Medicine

Commentary: A ‘mix and match’ approach to SARS-CoV-2 vaccination – Nature Medicine

Related:

WHO warns against mixing and matching COVID vaccines.

Germany issues world’s strongest recommendation for mixing Covid-19 vaccines.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Commentary on Twitter

 

[Preprint] Covid-19: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity.

27 Jul, 2021 | 03:50h | UTC

News release: Longer interval between Covid-19 Pfizer vaccine doses boosts immunity – Newcastle University

Original Study (preprint): Sustained T cell immunity, protection and boosting using extended dosing intervals of BNT162b2 mRNA vaccine

Commentaries:

Commentary: Covid-19: Longer interval between Pfizer doses results in higher antibody levels, research finds – BMJ

Expert reaction to preprint from PITCH study looking at interval between two Pfizer vaccine doses, and antibody and T-cell responses – Science Media Centre

Related:

Debate: Should we delay second vaccine doses to give one dose of the Covid-19 vaccine to more people? (several texts on the subject)

 

Safety evaluation of the second dose of mRNA COVID-19 vaccines in patients with immediate reactions to the first dose.

27 Jul, 2021 | 03:42h | UTC

Safety Evaluation of the Second Dose of Messenger RNA COVID-19 Vaccines in Patients With Immediate Reactions to the First Dose – JAMA Internal Medicine

Commentaries:

Second COVID-19 mRNA vaccine dose found safe following allergic reactions to first dose – Massachusetts General Hospital

No anaphylaxis after second dose of mRNA COVID vaccine, study finds – CIDRAP

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.